Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The clinical impact of continued smoking in patients with breast and other hormone-dependent cancer: A systematic literature review.
Del Riccio M, Vettori V, Raimondi S, Lorini C, Masala G, Cattaruzza MS, Mazzarella L, Bonaccorsi G, Masiero M, Bendinelli B, Curigliano G, Pravettoni G, Pastore E, Gandini S, Caini S. Del Riccio M, et al. Among authors: curigliano g. Crit Rev Oncol Hematol. 2023 Apr;184:103951. doi: 10.1016/j.critrevonc.2023.103951. Epub 2023 Feb 18. Crit Rev Oncol Hematol. 2023. PMID: 36805551 Review.
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
Valenza C, Trapani D, Gandini S, Sposetti C, Boscolo Bielo L, Marra A, Giarratano T, Favero D, Cortesi L, Moscetti L, Pistelli M, Berardi R, Zambelli A, Lambertini M, Del Mastro L, Guarneri V, Vernieri C, Curigliano G. Valenza C, et al. Among authors: curigliano g. Eur J Cancer. 2023 Sep;190:112944. doi: 10.1016/j.ejca.2023.112944. Epub 2023 Jun 20. Eur J Cancer. 2023. PMID: 37437366
De-escalation in low-risk, HER2-positive breast cancer.
Geuna E, Curigliano G, Montemurro F. Geuna E, et al. Among authors: curigliano g. Lancet Oncol. 2023 Mar;24(3):200-201. doi: 10.1016/S1470-2045(23)00064-5. Lancet Oncol. 2023. PMID: 36858719 No abstract available.
The immunogram of inflammatory breast cancer.
Valenza C, Trapani D, Fusco N, Wang X, Cristofanilli M, Ueno NT, Curigliano G. Valenza C, et al. Among authors: curigliano g. Cancer Treat Rev. 2023 Sep;119:102598. doi: 10.1016/j.ctrv.2023.102598. Epub 2023 Jul 8. Cancer Treat Rev. 2023. PMID: 37437342 Review.
The multicenter experience in the multidisciplinary Italian breast units: a review and update.
Magnoni F, Tinterri C, Corso G, Curigliano G, Leonardi MC, Toesca A, Rocco N, Catalano F, Bianchi B, Lauria F, Caldarella P, Pagani G, Galimberti V, Veronesi P. Magnoni F, et al. Among authors: curigliano g. Eur J Cancer Prev. 2024 May 1;33(3):185-191. doi: 10.1097/CEJ.0000000000000853. Epub 2023 Nov 6. Eur J Cancer Prev. 2024. PMID: 37997909 Review.
New Concepts in Cardio-Oncology.
Zagami P, Nicolò E, Corti C, Valenza C, Curigliano G. Zagami P, et al. Among authors: curigliano g. Cancer Treat Res. 2023;188:303-341. doi: 10.1007/978-3-031-33602-7_12. Cancer Treat Res. 2023. PMID: 38175351
Corrigendum to "Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)" [Cancer Treatment Reviews 123 (2024) 102672].
Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Dri A, et al. Among authors: curigliano g. Cancer Treat Rev. 2024 Apr;125:102714. doi: 10.1016/j.ctrv.2024.102714. Epub 2024 Mar 16. Cancer Treat Rev. 2024. PMID: 38493647 No abstract available.
757 results